CXCR3是实体瘤患者的一个预后标志物和潜在靶点：一项荟萃分析。

CXCR3 is a prognostic marker and a potential target for patients with solid tumors: a meta-analysis.

作者信息

Zhang Yang, Xu Linjuan, Peng Minggang

机构信息

Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

出版信息

Onco Targets Ther. 2018 Feb 27;11:1045-1054. doi: 10.2147/OTT.S157421. eCollection 2018.

OBJECTIVE

To deeply verify the clinical significance of CXCR3 in prediction of cancer patients' prognosis.

DATA SOURCES

We performed a meta-analysis including 12 studies searched from PubMed, Web of Science, Embase, and Cochrane databases. A total of 1,751 patients were used to analyze the association between CXCR3 and patients' prognosis, based on either overall survival or time to tumor progression.

STUDY SELECTION

Studies evaluating CXCR3 expression for predicting prognosis in human solid tumors were included.

RESULTS

It showed that patients with higher expression of CXCR3 had significantly shorter OS (pooled hazard ratio =2.315, 95% CI: 1.162-4.611, =0.017). In addition, higher CXCR3 expression was associated with distant metastasis (yes vs no: pooled relative ratio [RR] =1.828, 95% CI: 1.140-2.931, =0.012) in solid tumors and indicated advanced tumor stage (III/IV vs I/II, RR =2.656, 95% CI: 1.809-3.900, <0.001) and lymph node metastasis (yes vs no: RR =2.28, 95% CI: 1.61-3.25, <0.001) in colorectal cancer.

CONCLUSION

Our study highlights the role of CXCR3 as a potential prognostic marker and a promising therapeutic target in solid tumors.

目的

深入验证CXCR3在预测癌症患者预后中的临床意义。

数据来源

我们进行了一项荟萃分析，纳入了从PubMed、Web of Science、Embase和Cochrane数据库检索到的12项研究。基于总生存期或肿瘤进展时间，共1751例患者用于分析CXCR3与患者预后之间的关联。

研究选择

纳入评估CXCR3表达以预测人类实体瘤预后的研究。

结果

结果显示，CXCR3表达较高的患者总生存期显著缩短（合并风险比=2.315，95%置信区间：1.162-4.611，P=0.017）。此外，在实体瘤中，CXCR3表达较高与远处转移相关（是与否：合并相对比[RR]=1.828，95%置信区间：1.140-2.931，P=0.012），在结直肠癌中提示肿瘤分期较晚（III/IV期与I/II期，RR=2.656，95%置信区间：1.809-3.900，P<0.001）以及淋巴结转移（是与否：RR=2.28，95%置信区间：1.61-3.25，P<0.001）。